Cowen analyst Joseph Thome weighed in on Ardelyx, Inc (NASDAQ: ARDX) following FDA briefing documents.The analyst commented, "Briefing docs were ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE